Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 13.44
ARWR's Cash to Debt is ranked lower than
56% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 49.03 vs. ARWR: 13.44 )
Ranked among companies with meaningful Cash to Debt only.
ARWR' s Cash to Debt Range Over the Past 10 Years
Min: 0  Med: 33.21 Max: No Debt
Current: 13.44
Equity to Asset 0.70
ARWR's Equity to Asset is ranked higher than
53% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ARWR: 0.70 )
Ranked among companies with meaningful Equity to Asset only.
ARWR' s Equity to Asset Range Over the Past 10 Years
Min: -39.56  Med: 0.76 Max: 0.95
Current: 0.7
-39.56
0.95
Interest Coverage N/A
ARWR's Interest Coverage is ranked lower than
55% of the 464 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ARWR: N/A )
Ranked among companies with meaningful Interest Coverage only.
ARWR' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: N/A Max: No Debt
Current: N/A
N/A
No Debt
F-Score: 1
Z-Score: 1.00
M-Score: -4.69
WACC vs ROIC
13.78%
-512.40%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -49521.51
ARWR's Operating margin (%) is ranked lower than
97% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -82.26 vs. ARWR: -49521.51 )
Ranked among companies with meaningful Operating margin (%) only.
ARWR' s Operating margin (%) Range Over the Past 10 Years
Min: -49521.51  Med: -3442.52 Max: -520.49
Current: -49521.51
-49521.51
-520.49
Net-margin (%) -48979.07
ARWR's Net-margin (%) is ranked lower than
97% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -80.77 vs. ARWR: -48979.07 )
Ranked among companies with meaningful Net-margin (%) only.
ARWR' s Net-margin (%) Range Over the Past 10 Years
Min: -48979.07  Med: -3192.77 Max: -513.78
Current: -48979.07
-48979.07
-513.78
ROE (%) -89.84
ARWR's ROE (%) is ranked lower than
78% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. ARWR: -89.84 )
Ranked among companies with meaningful ROE (%) only.
ARWR' s ROE (%) Range Over the Past 10 Years
Min: -225.02  Med: -94.07 Max: -28.66
Current: -89.84
-225.02
-28.66
ROA (%) -74.03
ARWR's ROA (%) is ranked lower than
81% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: -26.97 vs. ARWR: -74.03 )
Ranked among companies with meaningful ROA (%) only.
ARWR' s ROA (%) Range Over the Past 10 Years
Min: -154.73  Med: -76.38 Max: -22.16
Current: -74.03
-154.73
-22.16
ROC (Joel Greenblatt) (%) -1421.56
ARWR's ROC (Joel Greenblatt) (%) is ranked lower than
65% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -366.92 vs. ARWR: -1421.56 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ARWR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -11843.37  Med: -1977.04 Max: -584.83
Current: -1421.56
-11843.37
-584.83
Revenue Growth (3Y)(%) -18.60
ARWR's Revenue Growth (3Y)(%) is ranked lower than
72% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. ARWR: -18.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ARWR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -52 Max: 64.8
Current: -18.6
0
64.8
EBITDA Growth (3Y)(%) -2.10
ARWR's EBITDA Growth (3Y)(%) is ranked lower than
52% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -0.10 vs. ARWR: -2.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ARWR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -56.2  Med: -18.7 Max: 190.2
Current: -2.1
-56.2
190.2
EPS Growth (3Y)(%) -5.50
ARWR's EPS Growth (3Y)(%) is ranked lower than
51% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. ARWR: -5.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ARWR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -75.1  Med: -13.95 Max: 162.1
Current: -5.5
-75.1
162.1
» ARWR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

ARWR Guru Trades in Q3 2015

Paul Tudor Jones 17,447 sh (New)
Steven Cohen Sold Out
» More
Q4 2015

ARWR Guru Trades in Q4 2015

Paul Tudor Jones 41,313 sh (+136.79%)
» More
Q1 2016

ARWR Guru Trades in Q1 2016

Paul Tudor Jones Sold Out
» More
Q2 2016

ARWR Guru Trades in Q2 2016

Steven Cohen 256,101 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with ARWR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:NERV, NAS:OMER, NAS:XBIT, NAS:ENTA, OTCPK:ZLDPF, NAS:RETA, NAS:GERN, NAS:TLGT, OTCPK:TYMI, NAS:CTMX, NAS:ADXS, NAS:MCRB, NAS:ASND, NAS:RVNC, NAS:EPZM, NAS:ARNA, NAS:SPPI, NAS:XNPT, NAS:CXRX, NAS:ACRS » details
Traded in other countries:HDP1.Germany,
Arrowhead Research Corp is engaged in developing novel drugs to treat intractable diseases by silencing the genes. The Company's drug candidate ARC-520 is designed to treat chronic hepatitis B infection.

Arrowhead Pharmaceuticals Inc, formerly Arrowhead Research Corp was originally incorporated in South Dakota in the year 1989, and was reincorporated in Delaware in 2000. The Company is a biopharmaceutical company developing targeted RNAi therapeutics. The Company is leveraging its proprietary drug delivery technologies to develop drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Its pipeline includes clinical programs in chronic hepatitis B virus and partner-based programs in obesity and oncology. Its products include ARC-520, Adipotide. The Company controls 306 patents. The Company and its products are regulated by FDA under the Federal Food, Drug and Cosmetic Act (the FDCA), and other laws within the Public Health Service Act.

Ratios

vs
industry
vs
history
P/B 7.00
ARWR's P/B is ranked lower than
76% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. ARWR: 7.00 )
Ranked among companies with meaningful P/B only.
ARWR' s P/B Range Over the Past 10 Years
Min: 1.65  Med: 4.83 Max: 71.58
Current: 7
1.65
71.58
P/S 1737.50
ARWR's P/S is ranked lower than
98% of the 681 Companies
in the Global Biotechnology industry.

( Industry Median: 11.12 vs. ARWR: 1737.50 )
Ranked among companies with meaningful P/S only.
ARWR' s P/S Range Over the Past 10 Years
Min: 4.04  Med: 173.5 Max: 4132.5
Current: 1737.5
4.04
4132.5
EV-to-EBIT -4.47
ARWR's EV-to-EBIT is ranked lower than
99.99% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 23.40 vs. ARWR: -4.47 )
Ranked among companies with meaningful EV-to-EBIT only.
ARWR' s EV-to-EBIT Range Over the Past 10 Years
Min: -28.8  Med: -3.5 Max: -0.3
Current: -4.47
-28.8
-0.3
EV-to-EBITDA -4.64
ARWR's EV-to-EBITDA is ranked lower than
99.99% of the 264 Companies
in the Global Biotechnology industry.

( Industry Median: 20.40 vs. ARWR: -4.64 )
Ranked among companies with meaningful EV-to-EBITDA only.
ARWR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -30.8  Med: -3.7 Max: -0.4
Current: -4.64
-30.8
-0.4
Current Ratio 3.34
ARWR's Current Ratio is ranked lower than
60% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.28 vs. ARWR: 3.34 )
Ranked among companies with meaningful Current Ratio only.
ARWR' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 3.34 Max: 302.61
Current: 3.34
0.01
302.61
Quick Ratio 3.34
ARWR's Quick Ratio is ranked lower than
57% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. ARWR: 3.34 )
Ranked among companies with meaningful Quick Ratio only.
ARWR' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 5.15 Max: 302.61
Current: 3.34
0.01
302.61

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -63.70
ARWR's 3-Year Average Share Buyback Ratio is ranked lower than
88% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. ARWR: -63.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ARWR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -598.6  Med: -30.15 Max: 0
Current: -63.7
-598.6
0

Valuation & Return

vs
industry
vs
history
Price/Net Cash 21.73
ARWR's Price/Net Cash is ranked lower than
83% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. ARWR: 21.73 )
Ranked among companies with meaningful Price/Net Cash only.
ARWR' s Price/Net Cash Range Over the Past 10 Years
Min: 0.05  Med: 7.11 Max: 103.64
Current: 21.73
0.05
103.64
Price/Net Current Asset Value 17.38
ARWR's Price/Net Current Asset Value is ranked lower than
84% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 5.50 vs. ARWR: 17.38 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ARWR' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.04  Med: 7.22 Max: 70.89
Current: 17.38
0.04
70.89
Price/Tangible Book 11.53
ARWR's Price/Tangible Book is ranked lower than
80% of the 764 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. ARWR: 11.53 )
Ranked among companies with meaningful Price/Tangible Book only.
ARWR' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.04  Med: 6.63 Max: 54.5
Current: 11.53
0.04
54.5
Price/Median PS Value 10.07
ARWR's Price/Median PS Value is ranked lower than
97% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. ARWR: 10.07 )
Ranked among companies with meaningful Price/Median PS Value only.
ARWR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.03  Med: 0.57 Max: 21.41
Current: 10.07
0.03
21.41
Earnings Yield (Greenblatt) (%) -22.40
ARWR's Earnings Yield (Greenblatt) (%) is ranked lower than
70% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. ARWR: -22.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ARWR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -105.61  Med: 0 Max: 0
Current: -22.4
-105.61
0

More Statistics

Revenue (TTM) (Mil) $0.17
EPS (TTM) $ -1.40
Beta1.63
Short Percentage of Float16.56%
52-Week Range $3.07 - 9.36
Shares Outstanding (Mil)60.75

Analyst Estimate

Sep16
Revenue (Mil $)
EPS ($) -1.32
EPS w/o NRI ($) -1.32
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:ARWR

Headlines

Articles On GuruFocus.com
Arrowhead Research Making Headway In The RNAi Therapy Platform Mar 09 2015 
Weekly CEO Buys Highlight: NRP, OPK, GAM, KEY, ARWR Oct 20 2014 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 10 2011 
Weekly CFO Buys Highlight: JAZZ, VRTB, ASTM, ARWR, CGX Sep 04 2010 
Arrowhead Research Corp. Reports Operating Results (10-Q) May 13 2010 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 11 2010 
Arrowhead Research Corp. Reports Operating Results (10-K) Dec 22 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) Aug 10 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) May 15 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 09 2009 

More From Other Websites
Arrowhead (ARWR) Exited Third Quarter with a Strong Balance Sheet Aug 23 2016
ETF’s with exposure to Arrowhead Pharmaceuticals, Inc. : August 19, 2016 Aug 19 2016
ARROWHEAD PHARMACEUTICALS, INC. Financials Aug 18 2016
Coverage initiated on Arrowhead by Cantor Fitzgerald Aug 18 2016
Arrowhead Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARWR-US :... Aug 15 2016
Arrowhead Pharmaceuticals, Inc. :ARWR-US: Earnings Analysis: Q3, 2016 By the Numbers : August 12,... Aug 12 2016
Arrowhead Pharmaceuticals Closes $45 Million Private Offering Aug 12 2016
Arrowhead Pharmaceuticals Closes $45 Million Private Offering Aug 12 2016
ARROWHEAD PHARMACEUTICALS, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities, Other... Aug 10 2016
Edited Transcript of ARWR earnings conference call or presentation 9-Aug-16 8:30pm GMT Aug 09 2016
Arrowhead Reports Fiscal 2016 Third Quarter Results Aug 09 2016
Arrowhead Research reports 3Q loss Aug 09 2016
Arrowhead Research reports 3Q loss Aug 09 2016
ARROWHEAD PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 09 2016
Arrowhead Reports Fiscal 2016 Third Quarter Results Aug 09 2016
Arrowhead Pharmaceuticals Prices $45 Million Private Offering Aug 09 2016
Arrowhead Pharmaceuticals Prices $45 Million Private Offering Aug 09 2016
Q3 2016 Arrowhead Pharmaceuticals Inc Earnings Release - After Market Close Aug 09 2016
ETF’s with exposure to Arrowhead Pharmaceuticals, Inc. : August 8, 2016 Aug 08 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)